CD4 and myeloid sarcoma: On the other hand, in human MS, some treatments are associated with the depletion of the membrane antigen in CD4+ and CD8+ T cells by Campath-1H (anti-CD25 monoclonal antibody), which induces a decrease in the number of relapses and lesions, showing improvement in neurological responses (Friese and Fugger, 2005).